Faeth Therapeutics (FTH) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $18.80, -8.74% vs the prior close of $20.60.
- Volume 595.93K shares, 1.7x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
FTH slides 8.7% to $18.80, a 3-month low. Closed at $18.80, -8.74% vs the prior close of $20.60. Day range $18.29–$21.00, opened at $21.00.
FTH daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — FTH slides 8.7% to $18.80, a 3-month low
- Closed at $18.80, -8.74% vs the prior close of $20.60. Day range $18.29–$21.00, opened at $21.00.
- Volume was 595.93K shares, 1.7x its 50-day average of 356.15K.
- Price is -39.5% vs its 50-day average ($31.07) and -24.0% vs its 200-day average ($24.74).
- 52-week range $7.45–$42.14; today's close sits at 33% of that range, 55.4% below the 52-week high.
Oct 15, 2026 — FTH jumps 3.0% to $20.60
- Closed at $20.60, +3.00% vs the prior close of $20.00. Day range $19.90–$21.39, opened at $19.90.
- Volume was 231.70K shares, 0.6x its 50-day average of 359.18K.
- Price is -33.9% vs its 50-day average ($31.19) and -16.6% vs its 200-day average ($24.69).
- 52-week range $7.45–$42.14; today's close sits at 38% of that range, 51.1% below the 52-week high.
Oct 14, 2026 — FTH slides 7.0% to $20.00, a 3-month low, 3 down days in a row
- Closed at $20.00, -7.02% vs the prior close of $21.51. Day range $19.85–$21.26, opened at $20.93.
- Volume was 421.40K shares, 1.2x its 50-day average of 363.79K.
- Price is -36.0% vs its 50-day average ($31.27) and -18.8% vs its 200-day average ($24.63).
- 52-week range $7.45–$42.14; today's close sits at 36% of that range, 52.5% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — FTH slides 7.5% to $21.51, a 3-month low
- Closed at $21.51, -7.48% vs the prior close of $23.25. Day range $21.34–$23.53, opened at $23.29.
- Volume was 350.40K shares, 1.0x its 50-day average of 362.54K.
- Price is -31.4% vs its 50-day average ($31.38) and -12.5% vs its 200-day average ($24.57).
- 52-week range $7.45–$42.14; today's close sits at 41% of that range, 49.0% below the 52-week high.
Oct 12, 2026 — FTH slides 10.7% to $23.25, a 3-month low
- Closed at $23.25, -10.68% vs the prior close of $26.03. Day range $23.00–$26.00, opened at $26.00.
- Volume was 309.80K shares, 0.9x its 50-day average of 360.87K.
- Price is -26.2% vs its 50-day average ($31.49) and -5.2% vs its 200-day average ($24.51).
- 52-week range $7.45–$42.14; today's close sits at 46% of that range, 44.8% below the 52-week high.
Oct 9, 2026 — FTH rises 1.6% to $26.03
- Closed at $26.03, +1.64% vs the prior close of $25.61. Day range $25.21–$26.64, opened at $25.21.
- Volume was 197.20K shares, 0.5x its 50-day average of 360.68K — lighter than usual.
- Price is -17.6% vs its 50-day average ($31.57) and +6.5% vs its 200-day average ($24.44).
- 52-week range $7.45–$42.14; today's close sits at 54% of that range, 38.2% below the 52-week high.
Oct 8, 2026 — FTH rises 2.8% to $25.61
- Closed at $25.61, +2.77% vs the prior close of $24.92. Day range $23.67–$26.16, opened at $25.12.
- Volume was 346.30K shares, 1.0x its 50-day average of 358.96K.
- Price is -19.0% vs its 50-day average ($31.63) and +5.1% vs its 200-day average ($24.36).
- 52-week range $7.45–$42.14; today's close sits at 52% of that range, 39.2% below the 52-week high.
Oct 7, 2026 — FTH slides 7.3% to $24.92, a 1-month low, 3 down days in a row
- Closed at $24.92, -7.33% vs the prior close of $26.89. Day range $23.95–$27.02, opened at $26.71.
- Volume was 322.60K shares, 0.9x its 50-day average of 358.49K.
- Price is -21.4% vs its 50-day average ($31.70) and +2.6% vs its 200-day average ($24.28).
- 52-week range $7.45–$42.14; today's close sits at 50% of that range, 40.9% below the 52-week high.
- That makes 3 straight losses.
Oct 6, 2026 — FTH dips 0.8% to $26.89, a 1-month low
- Closed at $26.89, -0.77% vs the prior close of $27.10. Day range $26.00–$29.64, opened at $26.96.
- Volume was 289.10K shares, 0.8x its 50-day average of 359.89K.
- Price is -15.4% vs its 50-day average ($31.78) and +11.1% vs its 200-day average ($24.20).
- 52-week range $7.45–$42.14; today's close sits at 56% of that range, 36.2% below the 52-week high.
Oct 5, 2026 — FTH slides 4.4% to $27.10, a 1-month low
- Closed at $27.10, -4.41% vs the prior close of $28.35. Day range $25.78–$28.33, opened at $28.31.
- Volume was 412.80K shares, 1.2x its 50-day average of 354.22K.
- Price is -14.9% vs its 50-day average ($31.83) and +12.4% vs its 200-day average ($24.11).
- 52-week range $7.45–$42.14; today's close sits at 57% of that range, 35.7% below the 52-week high.
Oct 2, 2026 — FTH ends flat (+0.3%) to $28.35
- Closed at $28.35, +0.28% vs the prior close of $28.27. Day range $27.37–$29.50, opened at $28.32.
- Volume was 187.90K shares, 0.5x its 50-day average of 352.48K — lighter than usual.
- Price is -11.0% vs its 50-day average ($31.85) and +18.1% vs its 200-day average ($24.01).
- 52-week range $7.45–$42.14; today's close sits at 60% of that range, 32.7% below the 52-week high.
FTH latest news & SEC filings
Every SEC filing by or about FTH in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Sep 17, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
Sep 15, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 15, 2026 · Form 3 — New insider holdings
Initial insider ownership statement (Form 3) — a new director, officer or 10% owner disclosed their holdings
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 11, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 4, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$16.01M (prior year -$4.94M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$2.84 (prior year -$3.91) (loss narrowed vs Jun 30, 2025)
Aug 4, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 28, 2026 · Form 3 — New insider holdings
Initial insider ownership statement (Form 3) — a new director, officer or 10% owner disclosed their holdings
Jul 23, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
Jul 23, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jul 23, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jun 23, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Things to know before you trade FTH
- Last results release: Aug 4, 2026 (8-K Item 2.02). Previous ones: May 15, 2026, Mar 30, 2026, Nov 14, 2025. Based on that rhythm, the next report is likely around Nov 3, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 4.39% (largest 10.7%). That is a volatile stock.
- Liquidity: about 356.03K shares (≈$6.69M) trade per day on average.
- 52-week position: $18.80 vs a range of $7.45–$42.14 (33% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: 1:20 on Jun 17, 2025
- Insider trades (Form 4, last 12 months, recent 25 shown): 25 open-market buys, 0 sales; latest: Brian C Stephenson bought 600 shares on Jul 1, 2026.
- Latest filings: 8-K Sep 17, 2026; 10-Q Aug 4, 2026; 8-K Aug 4, 2026.
- Share count: 25.84M shares outstanding (Jul 30, 2026), +1948.7% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
FTH market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 21.00 | 21.00 | 18.29 | 18.80 | 595.93K |
| Oct 15, 2026 | 19.90 | 21.39 | 19.90 | 20.60 | 231.70K |
| Oct 14, 2026 | 20.93 | 21.26 | 19.85 | 20.00 | 421.40K |
| Oct 13, 2026 | 23.29 | 23.53 | 21.34 | 21.51 | 350.40K |
| Oct 12, 2026 | 26.00 | 26.00 | 23.00 | 23.25 | 309.80K |
| Oct 9, 2026 | 25.21 | 26.64 | 25.21 | 26.03 | 197.20K |
| Oct 8, 2026 | 25.12 | 26.16 | 23.67 | 25.61 | 346.30K |
| Oct 7, 2026 | 26.71 | 27.02 | 23.95 | 24.92 | 322.60K |
| Oct 6, 2026 | 26.96 | 29.64 | 26.00 | 26.89 | 289.10K |
| Oct 5, 2026 | 28.31 | 28.33 | 25.78 | 27.10 | 412.80K |
| Oct 2, 2026 | 28.32 | 29.50 | 27.37 | 28.35 | 187.90K |
| Oct 1, 2026 | 29.56 | 31.13 | 27.66 | 28.27 | 268.50K |
| Sep 30, 2026 | 28.49 | 30.18 | 27.67 | 29.74 | 356.50K |
| Sep 29, 2026 | 27.77 | 28.21 | 26.99 | 28.07 | 250.80K |
| Sep 28, 2026 | 27.84 | 28.17 | 26.58 | 27.77 | 195.60K |
| Sep 25, 2026 | 28.93 | 28.93 | 27.60 | 28.00 | 328.20K |
| Sep 24, 2026 | 31.05 | 31.06 | 27.66 | 29.05 | 608.20K |
| Sep 23, 2026 | 32.71 | 33.95 | 31.34 | 31.55 | 435.00K |
| Sep 22, 2026 | 33.31 | 33.68 | 32.18 | 33.40 | 633.50K |
| Sep 21, 2026 | 34.50 | 34.81 | 32.11 | 33.29 | 379.10K |
About Faeth Therapeutics
Faeth Therapeutics (FTH) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in AUSTIN, TX. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1829802.
FTH board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Phillip B. Donenberg | Director | Jun 12, 2026 |
| Stephen M. Hahn | Director | Jun 16, 2026 |
| Bob Holmen | Director | Jun 12, 2026 |
| Anand Kiran Parikh | President and CEO | Jul 23, 2026 |
| Saira Ramasastry | Director | Jun 16, 2026 |
| Karen H Vousden | Director | Sep 15, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Josiah Craver | PAO | Jul 23, 2026 |
| Christopher Gerry | President & PEO | Jun 12, 2026 |
| Anand Kiran Parikh | President and CEO | Jul 23, 2026 |
| Brian C Stephenson | Chief Financial Officer | Jul 1, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jul 1, 2026 | Brian C Stephenson | Buy | 600 | $24.22 |
| Jul 1, 2026 | Brian C Stephenson | Buy | 4,400 | $23.40 |
| Jul 1, 2026 | Brian C Stephenson | Buy | 600 | $24.22 |
| Jul 1, 2026 | Brian C Stephenson | Buy | 4,400 | $23.40 |
| Jul 1, 2026 | Brian C Stephenson | Buy | 600 | $24.22 |
| Jul 1, 2026 | Brian C Stephenson | Buy | 4,400 | $23.40 |
| Jul 1, 2026 | Brian C Stephenson | Buy | 600 | $24.22 |
| Jul 1, 2026 | Brian C Stephenson | Buy | 4,400 | $23.40 |
| Jun 30, 2026 | Brian C Stephenson | Buy | 1,638 | $23.88 |
| Jun 30, 2026 | Brian C Stephenson | Buy | 1,910 | $22.95 |
| Jun 30, 2026 | Brian C Stephenson | Buy | 4,255 | $24.98 |
| Jun 30, 2026 | Brian C Stephenson | Buy | 1,638 | $23.88 |
| Jun 30, 2026 | Brian C Stephenson | Buy | 1,910 | $22.95 |
| Jun 30, 2026 | Brian C Stephenson | Buy | 4,255 | $24.98 |
| Jun 30, 2026 | Brian C Stephenson | Buy | 1,638 | $23.88 |
FTH financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-21.09M | -16.72 | $-20.45M |
| Dec 31, 2024 | — | $-30.16M | -24.01 | $-24.67M |
| Dec 31, 2023 | — | $-34.10M | -1.22 | $-32.02M |
| Dec 31, 2022 | — | $-48.59M | -1.58 | $-39.03M |
| Dec 31, 2021 | — | $-36.79M | -1.33 | $-30.26M |
Latest balance sheet: total assets $189.31M, total liabilities $9.58M, cash $26.90M (as of Jun 30, 2026).
FTH earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 4, 2026 | 8-K Item 2.02 (results) | $25.50 |
| May 15, 2026 | 8-K Item 2.02 (results) | $20.43 |
| Mar 30, 2026 | 8-K Item 2.02 (results) | $25.13 |
| Nov 14, 2025 | 8-K Item 2.02 (results) | $8.01 |
| Aug 5, 2025 | 8-K Item 2.02 (results) | $8.24 |
| May 6, 2025 | 8-K Item 2.02 (results) | $7.94 |
| Mar 28, 2025 | 8-K Item 2.02 (results) | $10.16 |
| Nov 14, 2024 | 8-K Item 2.02 (results) | $9.24 |
| Aug 6, 2024 | 8-K Item 2.02 (results) | — |
| May 9, 2024 | 8-K Item 2.02 (results) | — |
| Feb 28, 2024 | 8-K Item 2.02 (results) | — |
| Nov 7, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on FTH
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.